Hirayama Junya, Fujisawa Takao, Nagao Mizuho, Kuwabara Yu, Kainuma Keigo, Azuma Yoshinori, Ono Junya, Ohta Shoichiro, Hirayama Masahiro, Izuhara Kenji
Allergy Center, National Hospital Organization Mie National Hospital, Tsu, Japan.
Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
Asia Pac Allergy. 2021 Oct 25;11(4):e42. doi: 10.5415/apallergy.2021.11.e42. eCollection 2021 Oct.
We recently reported that squamous cell carcinoma antigen 2 (SCCA2) is a reliable biomarker for atopic dermatitis (AD).
To further clarify its utility, we investigated for effects of comorbid allergies and AD treatment on serum SCCA levels.
Volunteers <18 years old were recruited through our website. Their allergic status was elucidated using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire. We also recruited pediatric patients who were hospitalized because of severe AD. The serum levels of SCCA1 and SCCA2 were measured by enzyme-linked immunosorbent assays. In the severe AD patients, the levels of thymus and activation-regulated chemokine (TARC), SCCA1, and SCCA2 were measured before and after hospitalization. The severity of AD was assessed using the severity scoring of atopic dermatitis (SCORAD).
A total of 576 participants (547 volunteers and 29 patients) were enrolled in the study. The levels of SCCA1 and SCCA2 were significantly higher in volunteers with mild AD and patients with severe AD than in healthy volunteers without allergic diseases. The levels were not elevated in those who had mild bronchial asthma or allergic rhinitis without AD. TARC, SCCA1, and SCCA2 were decreased during the treatment in severe AD patients, reflecting clinical improvement in response to treatment. Linear regression analysis for predicting a decrease in the SCORAD index showed values of 0.16, 0.38, and 0.48 for TARC, SCCA1, and SCCA2, respectively.
SCCAs, especially SCCA2, are sensitive biomarkers for detecting AD in children and adolescents and for assessing the severity and response to treatment of severe AD.
我们最近报道，鳞状细胞癌抗原2（SCCA2）是特应性皮炎（AD）的可靠生物标志物。
为进一步阐明其效用，我们研究了合并过敏和AD治疗对血清SCCA水平的影响。
通过我们的网站招募了年龄小于18岁的志愿者。使用儿童哮喘和过敏国际研究（ISAAC）问卷阐明他们的过敏状态。我们还招募了因重度AD住院的儿科患者。通过酶联免疫吸附测定法测量血清SCCA1和SCCA2水平。在重度AD患者中，在住院前后测量胸腺和活化调节趋化因子（TARC）、SCCA1和SCCA2的水平。使用特应性皮炎严重程度评分（SCORAD）评估AD的严重程度。
共有576名参与者（547名志愿者和29名患者）纳入研究。轻度AD志愿者和重度AD患者的SCCA1和SCCA2水平显著高于无过敏性疾病的健康志愿者。在无AD的轻度支气管哮喘或过敏性鼻炎患者中，这些水平未升高。重度AD患者在治疗期间TARC、SCCA1和SCCA2降低，反映出对治疗的临床反应改善。预测SCORAD指数降低的线性回归分析显示，TARC、SCCA1和SCCA2的值分别为0.16、0.38和0.48。
SCCAs，尤其是SCCA2，是检测儿童和青少年AD以及评估重度AD严重程度和治疗反应的敏感生物标志物。
